Upstream stimulatory factor 1 associated with familial combined hyperlipidemia, LDL cholesterol, and triglycerides

Positive evidence has been reported for linkage and association between the upstream stimulatory factor 1 gene (USF1) and familial combined hyperlipidemia (FCHL). We genotyped the two most positive single-nucleotide polymorphisms (SNPs) (usf1s1: rs3737787 and usf1s2: rs2073658) from previous studies in a large family sample. This sample included 2,195 subjects in 87 Utah pedigrees ascertained for early death due to coronary heart disease (CHD), early strokes, or early onset hypertension. There were a total of 262 relative pairs in these families with FCHL. In the full family sample, FCHL was associated with usf1s1 (P=0.02). Triglyceride and LDL cholesterol defined qualitatively or quantitatively were also associated with usf1s1 (P=0.02–0.05). Results were strengthened for qualitative and quantitative triglyceride and LDL cholesterol when data from males only was analyzed, revealing associations for usf1s1 (P=0.001–0.02), usf1s2 (P=0.02–0.05) and the haplotype of these two SNPs (P=0.01–0.04). The strongest results were in the subset of subjects from families ascertained for premature stroke or hypertension, rather than those ascertained for premature CHD. This study replicates the involvement of USF1 in FCHL and related lipid traits in a family sample not ascertained for FCHL.     

Lack of association of glutamate decarboxylase 2 gene polymorphisms with severe obesity in utah

Three polymorphisms of the glutamate decarboxylase 2 gene, which encodes the glutamic acid decarboxylase enzyme, have been associated with severe obesity in a large French cohort. One of these polymorphisms was shown to have functional consequences on promoter expression. Another polymorphism was associated with insulin levels and secretion. These associations were examined in 855 severely obese Utah subjects (mean BMI = 48 kg/m(2)) and a normal-weight and normoglycemic subset (N = 130, mean BMI = 22 kg/m(2)) of a random sample of the Utah population (N = 462). Comparisons of the normal-weight random group with the severely obese group did not result in significant genotype or allele frequency differences for any of the three polymorphisms, C61450A, T83897A, or A-243G (all p > or = 0.18). Haplotypes were also not related to severe obesity (p = 0.10). None of the polymorphisms was significantly related to fasting glucose, insulin levels, or homeostasis model assessment insulin resistance or secretion indices. This study of normal-weight and severely obese subjects from Utah does not provide evidence for involvement of the three genotyped polymorphisms in the glutamate decarboxylase 2 gene with obesity or with insulin- and glucose-related measures associated with obesity.     

一株可增强莱茵衣藻耐盐能力细菌MEZX29的分离与鉴定

【背景】水体中的藻类、细菌及这些微生物之间的相互作用对水体生态系统的功能有着重要作用。近年来,一些河流、湖泊等淡水资源的盐渍化不断加重,对水体生态系统造成严重影响。然而,高盐胁迫条件如何影响藻类与其他细菌的相互作用,以及是否存在能够促进藻类耐盐能力的有益细菌等问题尚未得到深入研究。【目的】分离和鉴定可以促进淡水藻类莱茵衣藻抗盐能力的细菌,并开展相关机制分析。【方法】通过富集培养、筛选和共接种实验,获得可以促进衣藻耐盐的细菌;基于活细胞浓度、叶绿素含量等参数评价衣藻在不同条件下的生长能力;对菌株进行16S rRNA基因序列分析和基因组分析,预测其可能的菌藻相互作用机制。【结果】获得一株在250-290 mmol/L NaCl条件下可以显著增强衣藻耐盐能力的菌株MEZX29,16S rRNA基因序列分析表明,该菌可能属于Rhodococcus qingshengii;基因组分析结果表明,该细菌含有参与糖代谢、乙烯合成、生物膜形成等途径的基因,这些基因可能在促进衣藻抗盐过程中起到重要作用。【结论】Rhodococcus qingshengiiMEZX29可以增强莱茵衣藻21gr抵抗高盐胁迫的能力,为研究藻类与其他微生物之间的有益相互作用提供了新的材料。     

Association of the FTO gene with BMI

Variants in the FTO gene have been strongly associated with obesity in a very large sample (38,759) of diabetic and control subjects. To replicate these findings, the previously reported SNP in the FTO gene (rs9939609, T/A) was genotyped in 5,607 subjects from five different Utah studies. The studies included a random sample of the Utah population, families selected for aggregation of extreme thinness, families selected for severe obesity, a series of unrelated severe obesity subjects, and families participating in a 25-year longitudinal study of cardiovascular disease and aging. Results show a strong significant increase in the rs9939609 A allele frequency with increasing BMI (P < 0.0001). In the longitudinal study, FTO genotypes were significantly associated with BMI at a baseline exam, a 2(1/2)-year follow-up exam and a 25-year follow-up exam using an additive genetic model. The mean genotype difference in BMI ranged from 1.3 to 2.1 kg/m(2) across exams. The genotype difference in BMI means was established in youth, and at-risk subjects under age 20 at baseline had a significantly larger 25-year BMI increase (10.0 for A/A; 9.7 for A/T, and 8.5 kg/m(2) for T/T, P = 0.05). We conclude that the BMI increases associated with FTO genotypes begin in youth and are maintained throughout adulthood.     

香蕉凝集素BanLec基因转化毕赤酵母及转化子的鉴定

以pMD-BanLec质粒为模板扩增BanLec基因片段,该片段经EcoR I/XbaI双酶切后定向克隆到同样经EcoRI/XbaI双酶切的pPICZα表达载体上。将连接产物转化感受态DH5α,用低盐Zeocin抗性LB固体培养基筛选阳性克隆菌落。将重组质粒电转化毕赤酵母菌GS115后,通过PCR鉴定目的基因整合入酵母菌的基因组中,将有助于进一步研究BanLec蛋白的表达,为探讨香蕉凝集素的活性及生化功能等奠定基础。     

CTA095, a Novel Etk and Src Dual Inhibitor,Induces Apoptosis in Prostate Cancer Cells and Overcomes Resistance to Src Inhibitors

Etk is a non-receptor tyrosine kinase, which provides a strong survival signal in human prostate cancer cells. Src, another tyrosine kinase that cross-activates with Etk, has been shown to play an important role in prostate cancer metastasis. Herein, we discovered a new class of Etk inhibitors. Within those inhibitors, CTA095 was identified as a potent Etk and Src dual inhibitor. CTA095 was found to induce autophagy as well as apoptosis in human prostate cancer cells. In addition, CTA095 inhibited HUVEC cell tube formation and “wound healing” of human prostate cancer cells, implying its role in inhibition of angiogenesis and metastasis of human prostate cancer. More interestingly, CTA095 could overcome Src inhibitor resistance in prostate cancer cells. It induces apoptosis in Src inhibitor resistant prostate cancer cells, likely through a mechanism of down regulation of Myc and BCL2. This finding indicates that simultaneously targeting Etk and Src could be a promising approach to overcome drug resistance in prostate cancer.